News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

PHARMAC funds two more heart drugs

PHARMAC is to subsidise two more drugs to help fight heart disease after reaching an innovative agreement with the drugs’ supplier, AstraZeneca.

PHARMAC is to fund a new, expensive blood pressure lowering drug called candesartan, which may be valuable for patients whose blood pressure is not adequately controlled on other drugs. The drug is significantly more expensive than the current options available.

As well, PHARMAC has agreed to subsidise a new low dose beta-blocker called metoprolol succinate. According to new evidence it may give another treatment option for some people with heart failure.

The funding of the drug has been made possible as part of a package where AstraZeneca has dropped the price of one of its older blood pressure treatments, felodipine, which belongs to a class of drugs known as DHP CCBs.

PHARMAC General Manager Wayne McNee says the AstraZeneca agreement is a good example of how a co-operative environment can help all parties, with patients in particular getting the benefit.

“By freeing up funding in one area, we are able to invest in new drugs which will give prescribers more tools in their arsenal to fight cardiovascular disease.”

He says the company will be working with PHARMAC to ensure that candesarten is used appropriately. Under a risk sharing arrangement, the company will have to pay PHARMAC back if the drug is over-used.

Candesarten will be fully subsidised from December 1. Low dose metoprolol will be available after it obtains approval from the Ministry of Health.

[ends]

For further information contact PHARMAC General Manager Wayne McNee.
Phone: (025) 429-212.

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Handcrafted Form: Rare Treasures From Japan

This unique exhibition at Expressions Whirinaki represents 90 everyday objects made by contemporary Japanese artisans who employ various traditional craft techniques made in regional workshops. The works used in daily life are crafted from raw materials with techniques appropriate to bringing out the best of its medium, balancing ease of use with aesthetic appeal. More>>

Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

ALSO:

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland